ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism
November 22, 2021Today, the U.S. Food and Drug Administration approved Voxzogo (vosoritide) injection to improve growth in children five years of age and older with achondroplasia and open epiphyses (growth plates）... -
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia
June 24, 2019BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia.
Pharma Sources Insight January 2025
